Introducing Applied Clinical Trials' EDC News, a newsletter with news, articles, and information about EDC, IT, and eClinical.
Medidata Raves On EDC
Medidata's Rave EDC product has been moving in some interesting circles. In addition to becoming CDISC compliant, the products' accreditation program has been expanded so that CROs and other partners may achieve graduated levels of Rave service and support. Read about the CDISC initiatives here and about the Certification program here.
Almac Clinical Technologies
Almac Clinical Technologies provides phone and internet based interactive clinical technology solutions that improve the quality and efficiency of the clinical trial process. Our offerings include IVRS/ IXRS, iTrial EDC & ePRO.
www.almacgroup.com
eResearchTechnology
EDC Now! From eRTEDC is Evolving. eRT believes there is a better way.Visit us at DIA Booth# 800 for a demonstration!
invivodata
Clinical trial sponsors talked. We listened. Introducing the SitePRO® Tablet-the right size for site-based ePRO.
Management Forum's The CTD: An Introductory Overview
July 2, 2008
Location | London, UK
Pharmaceutical Information Management 2008
July 14–16, 2008
Location | Philadelphia, PA
CfPIE's FDA Inspections of Clinical Data Systems
July 17–18, 2008
Location | Costa Mesa, CA
Thomas Wells
- appointed OmniComm's vice president of technical operations.
Jim Walker
- of Octagon Research Solutions is a finalist in the American Business Awards.
Alan Gelenberg
- joins Healthcare Technology Systems as president, chief executive officer. (PDF)
Tim Pratt of MedNet Solutions (Minnetonka, MN) offers his comment on for-profit conferences in our industry. Click here to read more.
XClinical, a Germany-based EDC software vendor, participated in the CDISC Interchange in Japan earlier this month. Click here to read more.
Oncology-focused CRO ACORN (Memphis, TN) made its proprietary EDC system available to the clinical trials market. See the company press release here.
You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
2 Commerce Drive
Cranbury, NJ 08512